Evidence map›Paper›PMID 30730284›Full record

ArticleRadiation research2019

The Aftermath of Surviving Acute Radiation Hematopoietic Syndrome and its Mitigation.

Ewa D Micewicz, Keisuke S Iwamoto, Josephine A Ratikan, Christine Nguyen, Michael W Xie, Genhong Cheng, Gayle M Boxx, Elisa Deriu, Robert D Damoiseaux, Julian P Whitelegge and 9 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiation research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Radiation-induced tissue damage and response.The Journal of pathology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 3 countries.

Ewa D Micewicza Department of Radiation Oncology, University of California at Los Angeles, Los Angeles, California.
Keisuke S Iwamotoa Department of Radiation Oncology, University of California at Los Angeles, Los Angeles, California.
Josephine A Ratikana Department of Radiation Oncology, University of California at Los Angeles, Los Angeles, California.
Christine Nguyena Department of Radiation Oncology, University of California at Los Angeles, Los Angeles, California.
Michael W Xiea Department of Radiation Oncology, University of California at Los Angeles, Los Angeles, California.
Genhong Chengb Department of Microbiology, Immunology and Molecular Genetics, University of California at Los Angeles, Los Angeles, California.
Gayle M Boxxb Department of Microbiology, Immunology and Molecular Genetics, University of California at Los Angeles, Los Angeles, California.
Elisa Deriub Department of Microbiology, Immunology and Molecular Genetics, University of California at Los Angeles, Los Angeles, California.
Robert D Damoiseauxg Molecular Screening Shared Resource, University of California at Los Angeles, Los Angeles, California.
Julian P Whiteleggeh Pasarow Mass Spectrometry Laboratory, University of California at Los Angeles, Los Angeles, California.
Piotr P Ruchalah Pasarow Mass Spectrometry Laboratory, University of California at Los Angeles, Los Angeles, California.
Rozeta Avetisyanc Department of Anesthesiology, University of California at Los Angeles, Los Angeles, California.
Michael E Jungd Department of Chemistry and Biochemistry, University of California at Los Angeles, Los Angeles, California.
Greg Lawsone Department of Laboratory Animal Medicine, University of California at Los Angeles, Los Angeles, California.
Elizabeta Nemethf Department of Medicine, University of California at Los Angeles, Los Angeles, California.
Tomas Ganzf Department of Medicine, University of California at Los Angeles, Los Angeles, California.
James W Sayrei School of Public Health, Biostatistics and Radiology, University of California at Los Angeles, Los Angeles, California.
William H McBridea Department of Radiation Oncology, University of California at Los Angeles, Los Angeles, California.
Dörthe Schauea Department of Radiation Oncology, University of California at Los Angeles, Los Angeles, California.
IONICS Mass Spectrometry (Canada) · CAUniversity of California, Los Angeles · USMuhammad Nawaz Shareef University of Agriculture · PK

Funding

UCLA Center for Biological RadioprotectorsU19AI067769 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHUTE, JOHN P, MCBRIDE, WILLIAM H. · 2005 to 2019
$44.6M
NIAID NIH HHS U19 AI067769
6 · The paper itself

Abstract

Intensive research is underway to find new agents that can successfully mitigate the acute effects of radiation exposure. This is primarily in response to potential counterthreats of radiological terrorism and nuclear accidents but there is some hope that they might also be of value for cancer patients treated with radiation therapy. Research into mitigation countermeasures typically employs classic animal models of acute radiation syndromes (ARS) that develop after whole-body irradiation (WBI). While agents are available that successfully mitigate ARS when given after radiation exposure, their success raises questions as to whether they simply delay lethality or unmask potentially lethal radiation pathologies that may appear later in time. Life shortening is a well-known consequence of WBI in humans and experimental animals, but it is not often examined in a mitigation setting and its causes, other than cancer, are not well-defined. This is in large part because delayed effects of acute radiation exposure (DEARE) do not follow the strict time-dose phenomena associated with ARS and present as a diverse range of symptoms and pathologies with low mortality rates that can be evaluated only with the use of large cohorts of subjects, as in this study. Here, we describe chronically increased mortality rates up to 660 days in large numbers of mice given LD

Indexed as

Acute Radiation SyndromeAnimalsGastrointestinal MicrobiomeHeartHematopoietic SystemMaleMiceNeoplasms, Radiation-InducedRadiation-Protective AgentsSulfonamidesSurvival AnalysisRadiation-Protective AgentsSulfonamides

Identifiers

PMID30730284
PMCPMC6482953
OpenAlexW2912761243

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.